KR102696143B1 - 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역 - Google Patents

보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역 Download PDF

Info

Publication number
KR102696143B1
KR102696143B1 KR1020197030684A KR20197030684A KR102696143B1 KR 102696143 B1 KR102696143 B1 KR 102696143B1 KR 1020197030684 A KR1020197030684 A KR 1020197030684A KR 20197030684 A KR20197030684 A KR 20197030684A KR 102696143 B1 KR102696143 B1 KR 102696143B1
Authority
KR
South Korea
Prior art keywords
ser
thr
val
pro
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197030684A
Other languages
English (en)
Korean (ko)
Other versions
KR20190137821A (ko
Inventor
라메쉬 발리가
딘 엔쥐
Original Assignee
아이쥐엠 바이오사이언스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이쥐엠 바이오사이언스 인코포레이티드 filed Critical 아이쥐엠 바이오사이언스 인코포레이티드
Publication of KR20190137821A publication Critical patent/KR20190137821A/ko
Application granted granted Critical
Publication of KR102696143B1 publication Critical patent/KR102696143B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197030684A 2017-04-07 2018-04-06 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역 Active KR102696143B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483087P 2017-04-07 2017-04-07
US62/483,087 2017-04-07
PCT/US2018/026474 WO2018187702A2 (en) 2017-04-07 2018-04-06 Modified human igm constant regions for modulation of complement-dependent cytolysis effector function

Publications (2)

Publication Number Publication Date
KR20190137821A KR20190137821A (ko) 2019-12-11
KR102696143B1 true KR102696143B1 (ko) 2024-08-21

Family

ID=63713537

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197030684A Active KR102696143B1 (ko) 2017-04-07 2018-04-06 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역

Country Status (11)

Country Link
US (2) US11401337B2 (https=)
EP (1) EP3607091A4 (https=)
JP (3) JP2020512820A (https=)
KR (1) KR102696143B1 (https=)
CN (1) CN110536900B (https=)
AU (1) AU2018248336B2 (https=)
CA (1) CA3055790A1 (https=)
IL (1) IL268901B2 (https=)
MX (1) MX2019011986A (https=)
SG (1) SG11201908051RA (https=)
WO (1) WO2018187702A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
EP3957738A1 (en) 2015-03-04 2022-02-23 IGM Biosciences, Inc. Cd20 binding molecules and uses thereof
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN107847591B (zh) 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
MX2019011986A (es) * 2017-04-07 2019-11-07 Igm Biosciences Inc Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
MX2020009069A (es) 2018-03-01 2020-10-08 Igm Biosciences Inc Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero.
US20210380701A1 (en) * 2018-10-23 2021-12-09 Igm Biosciences, Inc. MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
JP2022544405A (ja) * 2019-08-15 2022-10-18 アイジーエム バイオサイエンシズ インコーポレイテッド 免疫刺激性多量体型結合分子
KR20220045030A (ko) * 2019-08-17 2022-04-12 아이쥐엠 바이오사이언스 인코포레이티드 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도
AU2020351205A1 (en) * 2019-09-19 2022-04-14 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
EP4139362A2 (en) 2020-04-22 2023-03-01 IGM Biosciences Inc. Pd-1 agonist multimeric binding molecules
US20240076392A1 (en) * 2021-02-17 2024-03-07 Igm Biosciences, Inc. Anti-cd123 binding molecules and uses thereof
AU2023216348A1 (en) * 2022-02-03 2024-06-20 Igm Biosciences, Inc. Anti-cd38 binding molecules and uses thereof
US20250326844A1 (en) 2022-04-07 2025-10-23 Repertoire Immune Medicines, Inc. T cell receptor multimers and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120316071A1 (en) 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
US20130089547A1 (en) 2011-09-26 2013-04-11 Jn Biosciences Llc Hybrid Constant Regions
WO2015129651A1 (ja) 2014-02-25 2015-09-03 富士レビオ株式会社 改変単量体ＩｇＭ
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256771A (en) 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US20150071948A1 (en) * 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
CN1922316B (zh) 2003-12-25 2011-03-23 协和发酵麒麟株式会社 抗cd40抗体突变体
DK1814913T3 (en) 2004-11-05 2015-09-28 Univ Leland Stanford Junior ANTIBODY-INDUCED CELL membrane damage.
WO2013120012A2 (en) 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
CA2922830A1 (en) 2013-09-05 2015-04-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
US9416496B2 (en) * 2013-10-16 2016-08-16 Georgia-Pacific Consumer Products Lp Method for reducing the bulk and increasing the density of a tissue product
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
EP3957738A1 (en) 2015-03-04 2022-02-23 IGM Biosciences, Inc. Cd20 binding molecules and uses thereof
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN107847591B (zh) 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
CN105441455B (zh) * 2015-10-21 2020-08-28 重庆金迈博生物科技有限公司 一种嵌合核酸分子及其在人源化抗体制备中的应用
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
AU2017299608A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric CD137/4-1BB binding molecules and uses thereof
JP2019530640A (ja) 2016-07-20 2019-10-24 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体ｏｘ４０結合分子及びその使用
MX2019000799A (es) 2016-07-20 2019-06-03 Igm Biosciences Inc Moleculas de union a gitr multimericas y usos de las mismas.
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF
MX2019011986A (es) * 2017-04-07 2019-11-07 Igm Biosciences Inc Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
EP3759229A4 (en) 2018-02-26 2021-12-29 IGM Biosciences Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
MX2020009069A (es) 2018-03-01 2020-10-08 Igm Biosciences Inc Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero.
US20210380701A1 (en) 2018-10-23 2021-12-09 Igm Biosciences, Inc. MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120316071A1 (en) 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
US20130089547A1 (en) 2011-09-26 2013-04-11 Jn Biosciences Llc Hybrid Constant Regions
WO2015129651A1 (ja) 2014-02-25 2015-09-03 富士レビオ株式会社 改変単量体ＩｇＭ
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides

Also Published As

Publication number Publication date
JP2023085503A (ja) 2023-06-20
CN110536900B (zh) 2024-06-11
IL268901A (en) 2019-10-31
IL268901B1 (en) 2025-07-01
EP3607091A4 (en) 2021-01-20
JP2020512820A (ja) 2020-04-30
AU2018248336A1 (en) 2019-09-26
AU2018248336B2 (en) 2024-10-03
SG11201908051RA (en) 2019-09-27
CA3055790A1 (en) 2018-10-11
MX2019011986A (es) 2019-11-07
IL268901B2 (en) 2025-11-01
US20210147567A1 (en) 2021-05-20
WO2018187702A2 (en) 2018-10-11
JP2024177479A (ja) 2024-12-19
EP3607091A2 (en) 2020-02-12
US11401337B2 (en) 2022-08-02
CN110536900A (zh) 2019-12-03
KR20190137821A (ko) 2019-12-11
US20220340676A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
KR102696143B1 (ko) 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역
KR102745232B1 (ko) IgM 혈청 반감기에 영향을 미치는 IgM Fc 및 J-쇄 돌연변이
JP6793655B2 (ja) Ｃｄ２０結合分子およびその使用方法
JP7585305B2 (ja) 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用
US20230203119A1 (en) Immunostimulatory multimeric binding molecules
US20220372142A1 (en) Multimeric antibodies with enhanced selectivity for cells with high target density
KR20230005228A (ko) Pd-1 효능제 다량체 결합 분자
KR20220050166A (ko) Igm 글리코변이체
KR20230146022A (ko) 항-cd123 결합 분자 및 이의 용도
KR20240139079A (ko) 항-cd38 결합 분자 및 이의 용도
BR112022002897B1 (pt) Anticorpo multimérico e biespecífico e uso do mesmo para tratar leucemia mieloide aguda

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191017

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210330

Comment text: Request for Examination of Application

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230316

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230712

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230316

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230712

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230515

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210813

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210330

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240112

Patent event code: PE09021S01D

PX0701 Decision of registration after re-examination

Patent event date: 20240729

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240813

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240814

End annual number: 3

Start annual number: 1

PG1601 Publication of registration